



**SMT announces Supraflex Cruz DES's  
Indication-based clinical data at PCR e-Course 2020**

- Indication-based clinical data underlines the safety and efficacy of Supraflex Cruz in as many as nine different clinical indications
- Supraflex Cruz is an ultrathin (60 µm) biodegradable polymer-coated sirolimus-eluting stent (SES) designed with a unique Long Dual Z (LDZ) link mounted on a cobalt-chromium platform

Mumbai, 29<sup>th</sup> June 2020

SMT (Sahajanand Medical Technologies Pvt. Ltd.), the largest stent manufacturer in the country announced that more than 8,000 patients' data was published in the *EuroPCR e-Course Abstract Book* as posters or oral presentations.

The data published includes data for patient subsets such as females (678 patients), young adults (464 patients), acute coronary syndrome (1,824 patients), STEMI (689 patients) diabetics (852 patients), and complex lesion subsets such as long coronary lesions  $\geq 28$  mm (1,241 patients), small coronary arteries  $\leq 2.5$  mm (726 patients), total occlusions (420 patients), and multivessel disease (406 patients).

The details of the published data are as below:

<b>Title</b>	<b>Patients/Lesions Subsets</b>	<b>No. of Patients</b>
<b>Twelve months clinical outcomes after implantation of long ultra-thin strut biodegradable polymer-coated sirolimus-eluting stents in atherosclerotic coronary lesions (Euro20A-POS703)</b>	Long lesions ( $\geq 28$ mm)	1241
<b>Performance of ultra-thin strut biodegradable polymer-coated sirolimus-eluting stent in females with coronary artery disease: results of twelve months follow-up (Euro20A-POS702)</b>	Female patients	678
<b>Clinical performance of ultra-thin strut biodegradable polymer-coated sirolimus-eluting stents in young patients with coronary artery disease: results of twelve months outcomes (Euro20A-POS699)</b>	Young patients	464
<b>Evaluation of ultra-thin strut biodegradable polymer-coated sirolimus-eluting stent in patients with small coronary arteries (<math>\leq 2.5</math> mm) (Euro20A-POS651)</b>	Small coronary arteries ( $\leq 2.5$ mm)	726
<b>Evaluation of clinical outcomes after ultra-thin strut (60 µm) biodegradable polymer-coated sirolimus-</b>	Acute coronary syndrome patients	1824



eluting stent implantation in patients with acute coronary syndrome (Euro20A-POS650)		
One-year clinical outcomes of ultrathin biodegradable polymer coated sirolimus eluting stents in total occlusion: a multicentre, all-comer analysis (Euro20A-OP124)	Total occlusion	420
One-year clinical outcomes of ultrathin biodegradable polymer coated sirolimus eluting stents for multivessel treatment (Euro20A-POS646)	Multivessel disease	406
One-year clinical outcomes of ultra-thin strut (60 µm) biodegradable polymer-coated sirolimus-eluting coronary stents in diabetic patients (Euro20A-POS624)	Diabetic patients	852
Twelve-month clinical outcomes of an ultra-thin (60 µm) strut, biodegradable polymer-coated, sirolimus-eluting coronary stent in STEMI patients – A real-world, multi-center experience (Euro20A-POS623)	STEMI patients	689
Clinical outcomes of biodegradable polymer-coated ultra-thin strut sirolimus-eluting stents in a 'real-World' patient population: Two-year results from the T-Flex registry (Euro20A-POS652)	All-comer patients	1203

\*Supraflex Cruz is a trademark of Sahajanand Medical Technologies Pvt. Ltd. or its affiliates. Specifications are subject to modification, revision and improvement.

\*The CE Mark indicates that the product satisfies requirements of EU Directives (EU : The European Union) and all products need to be CE certified to be sold in Europe.

---

### **About SMT (Sahajanand Medical Technologies)**

SMT is a global medical device company committed to making advance medical technologies accessible to everyone around the world. With a presence in over 75 countries, SMT has achieved recognition from the Government of India for its tremendous contributions in the field of Cardiovascular healthcare. SMT has also led the development of innovative biodegradable polymer coating technology in coronary stent system. SMT will continue the journey to healing hearts around the world by creating a healthcare future promising for everyone.



Published by *EuroIntervention*, this supplement comprises a selection of the community's 2020 abstracts accepted for oral or moderated e-Poster presentation, the PCR's Got Talent competition and as posters.

---

Media Contact:

Tejaswini Kamalkar

Manager | Corporate Communications

[tejaswini.kamalkar@smt.in](mailto:tejaswini.kamalkar@smt.in)

8291 371332 / 9930 456453